Table 3.
Overall 95% Confidence Interval of the major toxicities.
| Type of adverse event (n = 14) | Any grade N (%; 95%CI) |
Grade 3–4 N (%; 95%CI) |
Grade 1–2 N (%; 95%CI) |
|---|---|---|---|
| Haematological | |||
| Anemia | 11 (78; 54–100) | 1 (7; 0–23) | 10 (71; 44–98) |
| Neutropenia | 8 (57; 27–87) | 2 (14; 0–35) | 6 (43; 13–72) |
| Lymphopenia | 8 (57; 27–87) | 1 (7; 0–23) | 7 (50; 20–80) |
| Leukopenia | 6 (43; 13–72) | 0 (0) | 6 (43; 13–72) |
| Thrombocytopenia | 3 (21; 0–46) | 0 (0) | 3 (21; 0–46) |
| Non-haematological | |||
| ALT/GPT increased | 12 (86; 65–100) | 7 (50; 20–80) | 5 (36; 7–64) |
| AST/GOT increased | 12 (86; 65–100) | 0 | 12 (86; 65–100) |
| Nausea | 7 (50; 20–80) | 0 | 7(50; 20–80) |
| Fatigue | 6 (43; 13–72) | 0 | 6 (43; 13–72) |
| Skin disorders (dermatitis, epitelitis, erythema) | 5 (36; 7–64) | 1 (7; 0–23) | 4 (29; 1–56) |
| GGT increased | 10 (71; 44–98) | 1 (7; 0–23) | 9 (64; 36–93) |
| Anorexia | 4 (28; 1–56) | 0 | 4 (28; 1–56) |
| CPK increased | 4 (29; 1–56) | 0 | 4 (29; 1–56) |